Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship

Bodai, Balazs I.; Nakata, Therese E

doi:10.7812/tpp/19.129

Cited by 42 publications

(43 citation statements)

References 229 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In particular, several studies have linked the microbiome to the initiation and progression of different types of cancer, including breast cancer [ 58 , 59 ]. Moreover, the cooperation of microbial communities’ imbalance with diet, obesity, estrogens and immune modulation has been considered an important promoter of breast cancer [ 12 , 62 ]. Notably, the majority of authors [ 16 – 19 , 24 , 36 , 37 , 61 – 64 ] note that their findings are hypothesis-generators and support further investigations to identify a microbial risk signature for breast cancer and potential microbial-based prevention and/or therapies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Microbiome composition indicate dysbiosis and lower richness in tumor breast tissues compared to healthy adjacent paired tissue, within the same women

et al. 2022

View full text Add to dashboard Cite

Background Breast cancer (BC) is the most common malignancy in women, in whom it reaches 20% of the total neoplasia incidence. Most BCs are considered sporadic and a number of factors, including familiarity, age, hormonal cycles and diet, have been reported to be BC risk factors. Also the gut microbiota plays a role in breast cancer development. In fact, its imbalance has been associated to various human diseases including cancer although a consequential cause-effect phenomenon has never been proven. Methods The aim of this work was to characterize the breast tissue microbiome in 34 women affected by BC using an NGS-based method, and analyzing the tumoral and the adjacent non-tumoral tissue of each patient. Results The healthy and tumor tissues differed in bacterial composition and richness: the number of Amplicon Sequence Variants (ASVs) was higher in healthy tissues than in tumor tissues (p = 0.001). Moreover, our analyses, able to investigate from phylum down to species taxa for each sample, revealed major differences in the two richest phyla, namely, Proteobacteria and Actinobacteria. Notably, the levels of Actinobacteria and Proteobacteria were, respectively, higher and lower in healthy with respect to tumor tissues. Conclusions Our study provides information about the breast tissue microbial composition, as compared with very closely adjacent healthy tissue (paired samples within the same woman); the differences found are such to have possible diagnostic and therapeutic implications; further studies are necessary to clarify if the differences found in the breast tissue microbiome are simply an association or a concausative pathogenetic effect in BC. A comparison of different results on similar studies seems not to assess a universal microbiome signature, but single ones depending on the environmental cohorts’ locations.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In this context, environmental and lifestyle factors might also modify cancer risk in both familial and sporadic BCs. Nevertheless, most of the factors contributing to BC are still not completely understood thereby limiting BC prevention and treatment measures [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Microbiome composition indicate dysbiosis and lower richness in tumor breast tissues compared to healthy adjacent paired tissue, within the same women

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Overall, the microbiome of women with breast cancer contrasts from that of healthy women in terms of the number, kinds, abundance, and quality of species (e.g., at the metabolic and immunological levels). As a result, the microbiome has the potential to be an additional risk factor and forecaster of breast cancer, impacting therapy options [ 79 ].…”

Section: Finding Biomarkersmentioning

confidence: 99%

Drug Metabolism for the Identification of Clinical Biomarkers in Breast Cancer

Costa

Vale

2022

IJMS

View full text Add to dashboard Cite

Breast cancer is classified into four major molecular subtypes, and is considered a heterogenous disease. The risk profiles and treatment of breast cancer differ according to these subtypes. Early detection dramatically improves the prospects of successful treatment, resulting in a reduction in overall mortality rates. However, almost 30% of women primarily diagnosed with the early-stage disease will eventually develop metastasis or resistance to chemotherapies. Immunotherapies are among the most promising cancer treatment options; however, long-term clinical benefit has only been observed in a small subset of responding patients. The current strategies for diagnosis and treatment rely heavily on histopathological examination and molecular diagnosis, disregarding the tumor microenvironment and microbiome involving cancer cells. In this review, we aim to praise the use of pharmacogenomics and pharmacomicrobiomics as a strategy to identify potential biomarkers for guiding and monitoring therapy in real-time. The finding of these biomarkers can be performed by studying the metabolism of drugs, more specifically, immunometabolism, and its relationship with the microbiome, without neglecting the information provided by genetics. A larger understanding of cancer biology has the potential to improve patient care, enable clinical decisions, and deliver personalized medicine.

show abstract

“…The immune system is somehow affected by host immune factors as well as numerous non-host factors, for example, the combination of commensal microbiota, 87 diet, 88 and lifestyle. 89 The ability of the commensal microbes to regulate host gene expression factors, especially immune system modulators, has been considered over the past few decades. 90 Several experiments have shown dramatic changes in gene expression upon the introduction of microbial communities in laboratory animals.…”

Section: Metagenomics and Its Effect On The Immune Systemmentioning

confidence: 99%

Metagenomics studies for the diagnosis and treatment of prostate cancer

et al. 2021

View full text Add to dashboard Cite

Aim: Mutation occurs in the prostate cell genes, leading to abnormal prostate proliferation and ultimately cancer. Prostate cancer (PC) is one of the most common cancers amongst men, and its prevalence worldwide increases relative to men's age. About 16% of the world's cancers are the result of microbes in the human body.Impaired population balance of symbiosis microbes in the human reproductive system is linked to PC development.Discussion: With the advent of metagenomics science, the genome sequence of the microbiota of the human body has been unveiled. Therefore, it is now possible to identify a higher range of microbiome changes in PC tissue via the Next Generation Technique, which will have positive consequences in personalized medicine. In this review, we intend to question the role of metagenomics studies in the diagnosis and treatment of PC. Conclusion:The microbial imbalance in the men's genital tract might have an effect on prostate health. Based on next-generation sequencing-generated data, Proteobacteria, Firmicutes, Actinobacteria, and Bacteriodetes are the nine frequent phyla detected in a PC sample, which might be involved in inducing mutation in the prostate cells that cause cancer.

show abstract

Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship

Cited by 42 publications

References 229 publications

Microbiome composition indicate dysbiosis and lower richness in tumor breast tissues compared to healthy adjacent paired tissue, within the same women

Microbiome composition indicate dysbiosis and lower richness in tumor breast tissues compared to healthy adjacent paired tissue, within the same women

Drug Metabolism for the Identification of Clinical Biomarkers in Breast Cancer

Metagenomics studies for the diagnosis and treatment of prostate cancer

Contact Info

Product

Resources

About